Form 4: CARLSMED CEO Cordonnier Granted 117,316 RSUs

CARLSMED, Inc. CEO and President Michael Cordonnier was granted 117,316 restricted stock units, vesting over three years.

Summary

• Michael Cordonnier, CEO, President, and Director of CARLSMED, Inc. (CARL), acquired 117,316 shares of Common Stock.
• The transaction occurred on January 28, 2026, and was a grant of Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest in three equal annual installments, beginning on the first anniversary of the grant date.
• Following this transaction, Michael Cordonnier beneficially owns 1,356,646 shares of Common Stock.
• The acquisition price for these RSUs was $0.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily because it signifies continued executive commitment and aligns management's interests with long-term shareholder value, which is generally favorable.

Positives

• The grant of 117,316 Restricted Stock Units (RSUs) to the CEO and President aligns management's long-term interests with those of shareholders.
• RSUs are a common form of equity compensation designed to incentivize executive performance and retention.

Negatives

• The grant of RSUs at a $0 price indicates no immediate cash investment by the executive, which is typical for such grants.
• Future vesting of these RSUs will lead to dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• Future dilution of existing shareholders upon the vesting and conversion of the 117,316 Restricted Stock Units into common stock.
• The value of the RSUs is contingent on the future performance of CARLSMED's stock price, exposing the executive and the company to market volatility.

Future Outlook

The grant of Restricted Stock Units with a three-year annual vesting schedule indicates a long-term commitment from the CEO to the company's future performance and growth.

Management Comments

• Michael Cordonnier, as CEO, President, and Director, has acquired 117,316 Restricted Stock Units, demonstrating continued alignment with the company's long-term strategic objectives.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) to a top executive like Michael Cordonnier is a standard practice in the medical technology and broader corporate sectors. This form of equity compensation is widely used to attract, retain, and incentivize key personnel by linking their personal wealth directly to the company's stock performance, thereby aligning their interests with those of shareholders.

Comparison to Industry Standards

• The grant of RSUs to a CEO is a common executive compensation practice, comparable to similar grants observed at medical device companies such as Medtronic, Stryker, or Zimmer Biomet, where equity awards form a significant portion of executive pay.
• The three-year annual vesting schedule is typical for RSU grants, providing a balance between immediate incentive and long-term retention, consistent with industry benchmarks for executive equity awards.

Related Party Transactions

• The grant of 117,316 Restricted Stock Units to Michael Cordonnier, the CEO, President, and a Director, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of the CEO's interests with long-term company performance, but face potential future dilution upon RSU vesting.
• Employees: May view this as a positive signal of executive confidence and stability within the company.
• Management: Michael Cordonnier receives a significant equity award, incentivizing his continued leadership and commitment to the company's success.

Next Steps

• The Restricted Stock Units will vest in three equal annual installments, beginning on January 28, 2027, and continuing on January 28, 2028, and January 28, 2029.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) that aligns management's long-term interests with shareholders. While positive for corporate governance and executive retention, it does not present new fundamental information that would significantly alter the investment thesis for CARLSMED, warranting a 'hold' recommendation based solely on this filing.

Keywords

CARLSMED, CARL, Michael Cordonnier, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Stock Grant, Corporate Governance